Please assess the completion status of the following clinical trial:

Trial Title: ASpirin as a Treatment for ARDS (STAR): a Phase 2 Randomised Control Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients receiving invasive mechanical ventilation.~2. ARDS as defined by the Berlin definition.~   * Onset within 1 week of identified insult.~  * Within the same 24 hours~     * Hypoxic respiratory failure (PaO2/ FiO2 ratio ≤ 40kPa on PEEP ≥ 5 cmH20),~    * Bilateral infiltrates on chest X-ray consistent with pulmonary oedema not explained by another pulmonary pathology,~    * No evidence of heart failure or volume overload~Exclusion Criteria:~1. More than 72 hours from the onset of ARDS.~2. Age \< 16 years.~3. Patient is known to be pregnant.~4. Participation in a clinical trial of an investigational medicinal product within 30 days.~5. Current treatment with aspirin or within the past 4 weeks.~6. Platelet count \< 50 x 109/l.~7. Haemophilia or other haemorrhagic disorder or concurrent therapeutic anticoagulant therapy.~8. History of aspirin sensitive asthma or nasal polyps associated with asthma.~9. Active or history of recurrent peptic ulcer and/ or gastric/ intestinal haemorrhage or other kinds of bleeding such as cerebrovascular haemorrhage.~10. Traumatic brain injury.~11. Active gout.~12. Currently receiving methotrexate.~13. Severe chronic liver disease with Child-Pugh score \> 12.~14. Known hypersensitivity or previous adverse reaction to salicylic acid compounds or prostaglandin synthetase inhibitors.~15. Physician decision that aspirin is required for proven indication.~16. Contraindication to enteral drug administration, e.g. patients with mechanical bowel obstruction.~17. Treatment withdrawal imminent within 24 hours.~18. Consent declined.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aspirin 75mg (Type: EXPERIMENTAL): Aspirin 75mg enterally once daily for a maximum of 14 days
- Placebo (Type: PLACEBO_COMPARATOR): Lactose powder placebo enterally once daily for a maximum of 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).